Gilteritinib
Xospata · FLT3 inhibitor
Differentiation syndrome, tumor lysis and PRES in AML.
Rydapt · MID
FLT3 / multikinase inhibitor · approved 2017 · 7 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
First-generation FLT3/multikinase inhibitor added to induction in AML — its renal-relevant risks are treatment-related tumor lysis, edema and QT, not a direct nephrotoxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Given with intensive chemotherapy, the dominant toxicities are cytopenias, nausea/vomiting, mucositis, edema and QT changes; tumor lysis is a treatment-related (largely chemotherapy-driven) hazard. No characteristic or established midostaurin-specific direct nephrotoxicity is recognized apart from a single anecdotal case report of pauci-immune necrotizing glomerulonephritis, and AKI is multifactorial (volume loss, sepsis, TLS).Source: Stone et al., N Engl J Med 2017 (RATIFY); Stone et al., Blood Adv 2018
Tumor lysis early in induction; prerenal/electrolyte issues track intercurrent illness.
Distilled from: “Tumor lysis early in induction; prerenal/electrolyte issues track intercurrent illness; edema across treatment.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Oral multitargeted kinase inhibitor (a staurosporine derivative) that inhibits FLT3 (ITD and TKD), KIT, PDGFR, VEGFR2 and PKC. Added to 7+3 induction/consolidation it improves survival in newly diagnosed FLT3-mutated AML and is active in KIT-driven advanced systemic mastocytosis.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 1,957 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
472 of 1,957 reports
Reported with hospitalization
506 of 1,957 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Midostaurin sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Xospata · FLT3 inhibitor
Differentiation syndrome, tumor lysis and PRES in AML.
Poteligeo · Anti-CCR4 antibody
Tumor lysis and rare AKI; cutaneous T-cell lymphoma.
Monjuvi · Anti-CD19 antibody
Tumor lysis and infusion reactions in lymphoma.
Tazverik · EZH2 inhibitor
Tumor lysis; generally low direct renal toxicity.
Ayvakit · KIT / PDGFRA inhibitor
Edema, intracranial bleeding and cognitive effects.
Vanflyta · FLT3 inhibitor
2023 AML FLT3 inhibitor; tumor lysis and QT.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.